NCT03032536View on ClinicalTrials.gov

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions
Hepatitis BChronic Hepatitis BViral Hepatitis B
Interventions
DRUG

AL-3778

AL-3778 tablets or capsules

DRUG

Entecavir

Entecavir once daily for 14 days

DRUG

Tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate once daily for 14 days

Trial Locations (2)

1010

Auckland Clinical Studies, Auckland

8011

Christchurch Clinical Studies Trust, Christchurch

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT03032536 - Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers | Biotech Hunter | Biotech Hunter